Longbio Pharma (Suzhou) Co (HKSE:01779) Total Operating Expense: HK$175.56 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$113.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co Total Operating Expense?

Longbio Pharma (Suzhou) Co HKSE:01779 +5.51% 10 Total Operating Expense is HK$175.56 Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Longbio Pharma (Suzhou) Co's Total Operating Expense for the six months ended in Dec. 2025 was HK$175.56 Mil. Longbio Pharma (Suzhou) Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$175.56 Mil.

Longbio Pharma (Suzhou) Co Total Operating Expense Related Terms

Longbio Pharma (Suzhou) Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Total Operating Expense Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Total Operating Expense
115.46 175.56

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Total Operating Expense 115.46 175.56
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$175.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of HK$175.56 Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Total Operating Expense of HK$175.56 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Longbio Pharma (Suzhou) Co and its competitors.
Is Longbio Pharma (Suzhou) Co's Total Operating Expense too high?
Longbio Pharma (Suzhou) Co's current Total Operating Expense is HK$175.56 Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Total Operating Expense compare to VRTX and REGN?
Longbio Pharma (Suzhou) Co's Total Operating Expense of HK$175.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Total Operating Expense is HK$175.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Total Operating Expense of HK$175.56 Mil. The current Total Operating Expense is HK$175.56 Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Total Operating Expense is HK$175.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$113.00
Price